Immix Biopharma is a clinical-stage biopharmaceutical company focused on the development of chimeric antigen receptor (CAR-T) cell therapies for light chain (AL) amyloidosis and other serious diseases. The company's lead candidate, NXC-201, is a next-generation CAR-T therapy designed to treat relapsed/refractory AL amyloidosis, a condition characterized by the accumulation of abnormal proteins in vital organs. NXC-201 is currently being evaluated in the NEXICART-2 Phase 1b/2 clinical trial in the United States and the NEXICART-1 trial outside the U.S. The company utilizes its N-GENIUS platform to engineer cell therapies with specific modifications, including optimized CD3ζγ signaling, an enhanced CD8 hinge, and COBRA Binder Technology, aimed at improving efficacy and safety profiles. NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation, Orphan Drug Designation from both the FDA and the European Commission, and Breakthrough Therapy designation from the FDA for the treatment of relapsed/refractory AL amyloidosis. The company targets patients with this rare disease in the U.S. and international markets, with Memorial Sloan Kettering Cancer Center serving as the lead clinical site for the U.S. trial.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage immixbio.com
Sector Healthcare IR page immixbio.com/investors
Tags
car-t cell therapy, al amyloidosis, hematology, rare disease, cell therapy, oncology, immunotherapy, NXC-201, NEXICART-2, NEXICART-1, N-GENIUS, COBRA Binder Technology
Press page immixbio.com/latest-news

Metrics

Valuation  
Market cap $ 872.067M
Market cap (USD) $ 872.067M
P/E -12.54
PEG —
P/BV 2.60
P/S —
P/OCF -19.42
P/FCF -19.28
Dividend yield —
Turnover / mcap —
Returns  
ROE -55.0%
ROI -3,674.2%
ROIC -2,804.1%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 6
Quality score -63.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 104.84M 22.948M 19.925M 14.908M 18.192M 539.597K
Net profit -29.439M -21.613M -15.426M -8.23M -24.384M -1.148M
Free cash flow -24.663M -15.773M -11.424M -7.408M -1.59M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 5.23 2.2 6.92 2.29 3.56 —
Price performance 12m 1.38 -0.68 2.02 -0.36 — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — — 1.07M 1.07M
Cash and deposits (USD) 391,086 17.6M 13.4M 17.5M 17.7M 93.9M
Right-of-use assets (USD) — — — — 989,471 966,917
Cash flow detail
Operating cash flow (USD) -404,694 -1.59M -7.41M -11.4M -14.6M -23.9M
Purchases of property, plant and equipment (USD) — -802 — -52,089 -1.18M -732,925
Change in payables (cash effect) (USD) -3,830 -106,061 1.13M 2.43M — —
Share buybacks (cash effect) (USD) — — -99,963 — — —
Interest paid (cash effect) (USD) -899 -1,542 -9,596 — — —
Income taxes paid (cash effect) (USD) -17,547 — — — — —
Share-based compensation (USD) — 218,983 524,069 2.57M 3.02M 2.44M
Free cash flow (OCF - PPE - intangibles) (USD) — -1.59M — -11.4M -15.8M -24.7M
Income detail
Research and development expense (USD) 248,149 126,527 4.2M 8.74M 11.3M 16.3M
↳ 5y CAGR +130.8%
Total comprehensive income (USD) -1.08M -24.4M -8.27M -15.4M -21.7M -29.4M
Comprehensive income to owners (USD) -1.08M -24.4M -8.27M -15.4M -21.7M —
Reported Mar 28, 2022 Mar 28, 2022 Mar 27, 2023 Mar 29, 2024 Mar 25, 2025 Mar 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– Following positive NEXICART-2 clinical update, commercial launch preparation continues with commercial site activation activities, strengthened team, and provider and payer engagement –

– Interim NEXICART-2 clinical trial results selected for oral presentation at ASH 2026 –

LOS ANGELES, November 12, 2026 (GLOBE NEWSWIRE) – Immix Biopharma, Inc. (“Immix”, the “Company”, “we” or “us”), a global leader in AL amyloidosis, today reported an update on corporate progress and financial results for the quarter ended September 30, 2026.

Recent NXC-201 Progress

- Positive clinical data: 89% complete response rate was reported across all 45 NEXICART-2 patients, with MRD-negativity indicating potential to reach up to 98% complete response rate in the future.

- Immix continues to advance its AL Amyloidosis launch readiness activities across commercial site activation, provider and payer engagement, manufacturing activities, and healthcare professional education.

Immix plans for its BLA submission in mid-2027, and NEXICART-3 front line trial initiation in the first half of 2027.

LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. Morgan Healthcare Conference being held January 11-14, 2027 in San Francisco, CA.

A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.

About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

LOS ANGELES, CA, September 29, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The offering is expected to close on or about September 30, 2026, subject to the satisfaction of customary closing conditions.

Immix intends to use the net proceeds from this offering to fund NXC-201 development, working capital and general corporate purposes.

J.P. Morgan is acting as the sole book-running manager for the offering. The offering included participation from new and existing institutional investors, including Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments L.P., Wellington Management and other leading U.S. biotechnology institutional investors and mutual funds.

Prompts

Immix Biopharma, Inc. (ticker IMMX), listed in United States.

ETFs Holding Immix Biopharma, Inc.

ETF Weight in ETF Shares Market value As of
VFMO 0.14% 190,280 $ 2.67M Aug 31, 2026
RESM 0.02% 64 $ 659.84 Jun 30, 2026
AVSC 0.01% 48,823 $ 365.196K Nov 16, 2026